Every Form 4 that NextCure, Inc. (NXTC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow NXTC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NXTC filings page.
Simcere Zaiming, Inc., together with related reporting entities, reported the sale of 30,000 shares of NextCure, Inc. common stock on 2026-08-10 at $6.16 per share, held indirectly. After this transaction, 308,636 shares of common stock remained indirectly held. The reporting group states that, as a result of this sale, they ceased to be beneficial owners of more than 10% of NextCure’s common stock and therefore are no longer subject to Section 16 reporting for this issuer. Each reporting person disclaims beneficial ownership beyond their pecuniary interest.
Private investment funds managed by ADAR1 Capital Management, LLC, which may be deemed associated with Daniel Schneeberger, purchased a total of 329,153 shares of NextCure common stock on July 30–31, 2026 in multiple transactions at weighted-average prices generally between $4.7563 and $5.0000, reported as indirect holdings with beneficial ownership disclaimed except for any pecuniary interest.
NextCure, Inc. had open-market purchases of its common stock reported by 10% owners ADAR1 Capital Management, LLC and Daniel Schneeberger. Private investment funds managed by ADAR1 bought 17,608 shares between July 27 and July 29, 2026, at prices around $4.90–$5.00 per share. The securities are owned directly by those funds and may be deemed indirectly beneficially owned by ADAR1 and Schneeberger, who each disclaim beneficial ownership except to the extent of any pecuniary interest.
NextCure, Inc. director Elaine V. Jones reported receiving a stock option grant as compensation. She was awarded options to acquire 2,340 shares of common stock at an exercise price of $2.02 per share, expiring on June 17, 2036.
According to the filing, this option vests in full on the earlier of June 18, 2027 or the date of NextCure’s 2027 annual meeting of stockholders. This is an acquisition of derivative securities by a director, not an open‑market purchase or sale of common shares.
NextCure, Inc. director Ellen Feigal received a grant of stock options covering 2,340 shares of common stock. These options have an exercise price of $2.02 per share and expire on June 17, 2036.
The option vests in full on the earlier of June 18, 2027 or the date of NextCure’s 2027 Annual Meeting of Stockholders. Following this grant, Feigal holds 2,340 stock options directly related to this award.
NextCure, Inc. director Anne Elizabeth Borgman reported a grant of stock options covering 2,340 shares of common stock at an exercise price of $2.02 per share. The option vests in full on the earlier of June 18, 2027 and the 2027 Annual Meeting of Stockholders and expires on June 17, 2036. Following this grant, she holds 2,340 options directly.
NextCure, Inc. director Stephen W. Webster reported receiving a stock option grant covering 2,340 shares of common stock. The option has an exercise price of $2.02 per share and expires on June 17, 2036. It vests in full on the earlier of June 18, 2027 or the 2027 Annual Meeting of Stockholders, and reflects equity compensation rather than an open-market purchase or sale.
NextCure, Inc. director David S. Kabakoff received a stock option grant giving him the right to buy 3,510 shares of common stock at an exercise price of $2.02 per share as compensation. Following this award, he holds stock options for 3,510 shares directly.
The option vests in full on the earlier of June 18, 2027 or the date of NextCure’s 2027 annual stockholders’ meeting, meaning it becomes exercisable at that time. The option expires on June 17, 2036, providing a long-dated incentive tied to the company’s future performance.
NextCure, Inc. director John G. Houston reported a grant of stock options representing 2,340 shares of common stock. These options have an exercise price of $2.0200 per share and expire on June 17, 2036.
The option vests in full on the earlier of June 18, 2027 and the date of NextCure’s 2027 Annual Meeting of Stockholders, making this a routine, compensation-related award rather than an open-market purchase or sale. Following this grant, Houston holds options for 2,340 shares directly.
NextCure, Inc. reported that its Sr VP and General Counsel, Kevin G. Shaw, received an employee stock option grant. On January 30, 2026, he was awarded an option to buy 8,270 shares of common stock at an exercise price of $10.85 per share.
According to the vesting schedule, one fourth of the option vests on January 30, 2027, and the remaining three fourths vest in 36 monthly installments beginning February 28, 2027. Following this grant, he beneficially holds 8,270 stock options directly.
NextCure, Inc. reported that Senior Vice President of Development and Manufacturing Sourav K. Kundu received an employee stock option grant. On January 30, 2026, he was awarded options to buy 8,270 shares of common stock at an exercise price of $10.85 per share.
One fourth of the option vests on January 30, 2027, with the remaining portion vesting in 36 monthly installments beginning February 28, 2027. Following this grant, Kundu beneficially owns 8,270 stock options, all held directly.
NextCure, Inc. reported that its Chief Medical Officer, Udayan Guha, received an employee stock option grant on January 30, 2026. The option covers 14,670 shares of common stock at an exercise price of $10.85 per share and is held directly.
One quarter of the option vests on January 30, 2027, with the remaining three quarters vesting in 36 monthly installments starting February 28, 2027. The option expires on January 29, 2036 if not exercised.
NextCure, Inc. reported that its Chief Operating Officer, Timothy Mayer, received an award of employee stock options. The grant covers 14,670 options with an exercise price of $10.85 per share and was dated January 30, 2026.
One fourth of the option grant vests on January 30, 2027, with the remaining options vesting in 36 monthly installments beginning February 28, 2027. Mayer holds all 14,670 derivative securities directly following this award.
NextCure, Inc. reported that President and CEO Michael Richman received a grant of 38,190 employee stock options on January 30, 2026. These options have an exercise price of $10.85 per share and expire on January 29, 2036.
According to the vesting schedule, one fourth of the option grant vests on January 30, 2027, with the remaining options vesting in 36 equal monthly installments beginning on February 28, 2027. Following this grant, Richman beneficially owns 38,190 derivative securities directly.
NextCure, Inc. insider filing shows a new stock option grant to its Chief Financial Officer, Steven P. Cobourn. On January 30, 2026, he received an employee stock option to buy 14,670 shares of NextCure common stock at an exercise price of $10.85 per share.
According to the vesting schedule, one fourth of the option vests on January 30, 2027, with the remaining three fourths vesting in 36 equal monthly installments starting February 28, 2027. This type of award is a standard form of equity compensation that links executive pay to the company’s future stock performance.